In an exclusive 'Face the Nation' interview, Nobel laureate María Corina Machado discusses Venezuela's future after U.S. intervention, while domestic debates over ICE tactics and a partial government shutdown highlight deepening political divisions.
A significant purchase of the VictoryShares USAA Core Short-Term Bond ETF (USTB) by wealth manager Merit Financial Group highlights institutional interest in short-duration, income-focused strategies amid market uncertainty.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
A federal lawsuit alleging discriminatory hiring quotas and executive pay tied to demographic targets has placed Comerica's DEI governance under intense scrutiny. The legal challenge emerges as the regional bank navigates its planned acquisition by Fifth Third Bancorp, raising questions about regulatory hurdles and integration risks.
While Insas Berhad's (KLSE:INSAS) share price has underperformed the broader market over three years, its total shareholder return tells a different story. A closer look reveals a disconnect between stock performance and underlying business fundamentals, prompting investor scrutiny.
Driven by robust subscriber growth, a surge in free cash flow, and a new $10 billion buyback plan, AT&T's stock rallied over 10% this week, signaling renewed investor confidence in the telecom giant's convergence strategy.
Newly released court files detail Epstein's involvement with key Bitcoin figures, investment discussions, and his role in funding pivotal infrastructure projects during the industry's nascency.
Micron Technology, a key player in memory chips, is poised for explosive earnings growth fueled by insatiable AI demand. Yet, its cyclical nature and commoditized market pose significant long-term risks for investors.
Asset managers ramped up bearish bets against the U.S. dollar to their highest level in months, only to be blindsided by a sudden rally fueled by speculation that former Fed Governor Kevin Warsh is President Trump's pick to lead the central bank.
The Northern Ireland Executive has suspended a planned revaluation of hotel business rates, averting significant tax increases for accommodation providers slated for 2026 and providing temporary stability for the region's tourism industry.
The Hong Kong Monetary Authority has detailed its enhanced oversight framework for key retail payment systems, designating networks like Visa, Mastercard, and UnionPay for direct supervision to ensure security and stability in the city's rapidly digitizing economy.
As a significant equity rotation takes hold in early 2026, shifting focus from growth to value, dividend-focused ETFs are emerging as key beneficiaries for investors seeking yield and stability.
Shares of Brookdale Senior Living (BKD) have skyrocketed over 224% in the past year, drawing intense scrutiny from investors. As the stock hovers near analyst targets, the market debates whether its valuation still has room to run or if it's overheated in the face of sector headwinds.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
While investor attention fixates on flashier names, Marvell Technology's critical role in custom AI chips and data center infrastructure positions it for explosive growth, making its current valuation a potential opportunity.
An analysis of wealth accumulation among the world's top billionaires reveals staggering gains during the current presidential term, with policy and market dynamics fueling unprecedented fortunes.
While both ETFs target the high-flying U.S. technology sector, a closer look reveals critical distinctions in diversification, concentration risk, and liquidity that could sway long-term portfolio outcomes.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
In a revealing moment during Tesla's earnings call, Elon Musk disclosed that his Saturdays are dedicated to the company's next-generation AI5 chip project, signaling a fundamental strategic shift from automaker to vertically integrated AI hardware powerhouse.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
